Can ketamine be a safe option for treatment-resistant bipolar depression?
Author:
Affiliation:
1. Department of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA
Publisher
Informa UK Limited
Subject
Pharmacology (medical),General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.2045272
Reference15 articles.
1. Solovitch S. Onetime party drug hailed as miracle for treating severe depression. https://www.washingtonpost.com/national/health-science/a-one-time-party-drug-is-helping-people-with-deep-depression/2016/02/01/d3e73862-b490-11e5-a76a-0b5145e8679a_story.html Accessed 2021 Oct 25. The Washington Post Feb 1. 2016.
2. A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
3. Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial
4. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial
5. A Systematic Review on the Efficacy of Intravenous Racemic Ketamine for Bipolar Depression
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine;Journal of Affective Disorders;2024-04
2. An Update on the Efficacy of Single and Serial Intravenous Ketamine Infusions and Esketamine for Bipolar Depression: A Systematic Review and Meta-Analysis;Brain Sciences;2023-12-02
3. Attenuation of severe ketamine-induced neuropsychiatric side effects by lamotrigine in a patient with treatment resistant bipolar depression: A case report;Psychiatry Research Case Reports;2023-12
4. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report;Pharmaceuticals;2023-08-16
5. Progress in treatment‐resistant bipolar depression using repeated ketamine infusions;Bipolar Disorders;2023-06-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3